- /
 - Supported exchanges
 - / US
 - / GLAXF.PINK
 
GSK plc (GLAXF PINK) stock market data APIs
GSK plc Financial Data Overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get GSK plc data using free add-ons & libraries
Get GSK plc Fundamental Data
GSK plc Fundamental data includes:
- Net Revenue: 32 166 M
 - EBITDA: 9 519 M
 - Earnings Per Share: 1
 - Income Statements
 - Balance Sheets
 - Cash flows
 
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
 - EPS/Forecast: 0.47
 
What’s included:
- End of Day, Intraday and Live APIs
 - Splits
 - Dividends
 
GSK plc News
                            
                    New
                
                    GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
Gilead Sciences, Inc. GILD posted better-than-expected third-quarter 2025 results and lifted the lower end of its product sales. Adjusted earnings per share (EPS) of $2.47 beat the Zacks Consensus Est...
                    
                    How Recent Developments Are Shaping the GSK Investment Story
GSK’s fair value estimate has seen a modest increase, rising from $16.63 to $17.36 per share. The discount rate remains largely unchanged. This adjustment reflects shifts in analyst sentiment, drive...
                    GSK Rises 7% After Raising 2025 Profit Forecast
This article first appeared on GuruFocus. GSK (NYSE:GSK) rallied nearly 7% on Wednesday after delivering a stronger-than-expected third quarter and raising its 2025 profit outlook. The drugmaker now ...
                    Jefferies Bullish on GSK, Citing Growth Pipeline and Efficiency Prospects
GSK plc (NYSE:GSK) is included among the 11 Best FTSE Dividend Stocks to Buy Right Now.Jefferies Bullish on GSK, Citing Growth Pipeline and Efficiency Prospects Image by Alexsander-777 from Pixabay ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
 - Instant access: Get your API key and instructions within seconds of subscribing
 - Price stability: Locked-in rates for subscribed users, never changing
 
What’s included:
- API Calls per Day: 100 000/day
 - API Requests per Min.: 1000/minute
 - Type of Usage: Personal use
 
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.